annual CFO:
-$73.19M-$11.92M(-19.46%)Summary
- As of today (August 22, 2025), ELVN annual cash flow from operations is -$73.19 million, with the most recent change of -$11.92 million (-19.46%) on December 31, 2024.
- During the last 3 years, ELVN annual CFO has fallen by -$54.06 million (-282.52%).
- ELVN annual CFO is now -733.91% below its all-time high of -$8.78 million, reached on December 1, 2018.
Performance
ELVN Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
-$17.06M+$7.07M(+29.30%)Summary
- As of today (August 22, 2025), ELVN quarterly cash flow from operations is -$17.06 million, with the most recent change of +$7.07 million (+29.30%) on June 30, 2025.
- Over the past year, ELVN quarterly CFO has increased by +$3.38 million (+16.53%).
- ELVN quarterly CFO is now -164.57% below its all-time high of -$6.45 million, reached on September 30, 2022.
Performance
ELVN quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
-$70.58M+$3.38M(+4.57%)Summary
- As of today (August 22, 2025), ELVN TTM cash flow from operations is -$70.58 million, with the most recent change of +$3.38 million (+4.57%) on June 30, 2025.
- Over the past year, ELVN TTM CFO has increased by +$1.59 million (+2.21%).
- ELVN TTM CFO is now -640.84% below its all-time high of -$9.53 million, reached on March 1, 2020.
Performance
ELVN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ELVN Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -19.5% | +16.5% | +2.2% |
| 3 y3 years | -282.5% | -139.4% | -72.7% |
| 5 y5 years | -234.6% | -84.3% | -275.8% |
ELVN Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -282.5% | at low | -164.6% | +29.3% | -98.4% | +4.6% |
| 5 y | 5-year | -282.5% | at low | -164.6% | +29.3% | -275.8% | +4.6% |
| alltime | all time | -733.9% | at low | -164.6% | +29.3% | -640.8% | +4.6% |
ELVN Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$17.06M(-29.3%) | -$70.58M(-4.6%) |
| Mar 2025 | - | -$24.13M(+40.2%) | -$73.96M(+1.0%) |
| Dec 2024 | -$73.19M(+19.5%) | -$17.20M(+41.1%) | -$73.19M(+6.9%) |
| Sep 2024 | - | -$12.19M(-40.3%) | -$68.47M(-5.1%) |
| Jun 2024 | - | -$20.43M(-12.5%) | -$72.17M(+13.1%) |
| Mar 2024 | - | -$23.36M(+87.2%) | -$63.79M(+4.1%) |
| Dec 2023 | -$61.27M(+72.3%) | -$12.48M(-21.5%) | -$61.27M(+1.4%) |
| Sep 2023 | - | -$15.89M(+31.9%) | -$60.42M(+18.5%) |
| Jun 2023 | - | -$12.05M(-42.2%) | -$50.98M(+10.7%) |
| Mar 2023 | - | -$20.84M(+79.1%) | -$46.05M(+29.5%) |
| Dec 2022 | -$35.57M | -$11.64M(+80.5%) | -$35.57M(-2.3%) |
| Sep 2022 | - | -$6.45M(-9.5%) | -$36.42M(-10.9%) |
| Jun 2022 | - | -$7.12M(-31.2%) | -$40.87M(-7.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$10.36M(-17.0%) | -$44.11M(-5.7%) |
| Dec 2021 | -$19.13M(-48.8%) | - | - |
| Dec 2021 | - | -$12.48M(+14.5%) | -$46.77M(+9.9%) |
| Sep 2021 | - | -$10.90M(+5.2%) | -$42.55M(+1.3%) |
| Jun 2021 | - | -$10.37M(-20.4%) | -$42.00M(+2.7%) |
| Mar 2021 | - | -$13.02M(+57.5%) | -$40.89M(+9.3%) |
| Dec 2020 | -$37.40M(+70.9%) | -$8.27M(-20.1%) | -$37.40M(+28.4%) |
| Sep 2020 | - | -$10.35M(+11.8%) | -$29.13M(+55.1%) |
| Jun 2020 | - | -$9.26M(-2.8%) | -$18.78M(+97.2%) |
| Mar 2020 | - | -$9.53M | -$9.53M |
| Dec 2019 | -$21.88M(+149.3%) | - | - |
| Dec 2018 | -$8.78M(-0.1%) | - | - |
| Dec 2017 | -$8.79M | - | - |
FAQ
- What is Enliven Therapeutics, Inc. annual cash flow from operations?
- What is the all time high annual CFO for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. annual CFO year-on-year change?
- What is Enliven Therapeutics, Inc. quarterly cash flow from operations?
- What is the all time high quarterly CFO for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. quarterly CFO year-on-year change?
- What is Enliven Therapeutics, Inc. TTM cash flow from operations?
- What is the all time high TTM CFO for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. TTM CFO year-on-year change?
What is Enliven Therapeutics, Inc. annual cash flow from operations?
The current annual CFO of ELVN is -$73.19M
What is the all time high annual CFO for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high annual cash flow from operations is -$8.78M
What is Enliven Therapeutics, Inc. annual CFO year-on-year change?
Over the past year, ELVN annual cash flow from operations has changed by -$11.92M (-19.46%)
What is Enliven Therapeutics, Inc. quarterly cash flow from operations?
The current quarterly CFO of ELVN is -$17.06M
What is the all time high quarterly CFO for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high quarterly cash flow from operations is -$6.45M
What is Enliven Therapeutics, Inc. quarterly CFO year-on-year change?
Over the past year, ELVN quarterly cash flow from operations has changed by +$3.38M (+16.53%)
What is Enliven Therapeutics, Inc. TTM cash flow from operations?
The current TTM CFO of ELVN is -$70.58M
What is the all time high TTM CFO for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high TTM cash flow from operations is -$9.53M
What is Enliven Therapeutics, Inc. TTM CFO year-on-year change?
Over the past year, ELVN TTM cash flow from operations has changed by +$1.59M (+2.21%)